XTL Biopharmaceuticals, a biopharmaceutical development company based in Herzliya, Israel, announced it will acquire Kitov Pharmaceuticals. The company said it could pay up to $48 million through shares as well as cash milestone payments. Kitov Pharmaceuticals, which researches and develops combination drug products, has focused on the treatment of hypertension and pain induced by osteoarthritis. XTL focuses on the acquisition, development and commercialization of pharmaceutical products for the treatment of clinical unmet needs.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments